Molecular Metabolism· 2019Q1· Review
Glucagon-like peptide 1 (GLP-1)
- 1,761citations
- Q1SCImago
- 2019year
Short summary
Glucagon-like peptide-1 (GLP-1) is a hormone with broad therapeutic potential beyond its role in glucose regulation, showing promise for treating obesity, diabetes, and neurodegenerative disorders.
AI-generated from the title and abstract; the full text is not read.
Key points
- GLP-1 stimulates insulin secretion, reduces gastric emptying, and inhibits food intake.
- The hormone possesses cardio- and neuroprotective effects, decreases inflammation, and impacts learning and memory.
- Biochemically modified GLP-1 receptor agonists are approved for type-2 diabetes treatment.
- GLP-1-based therapies are under evaluation for obesity and neurodegenerative disorders.
AI-generated from the title and abstract; the full text is not read.
Abstract
BACKGROUND: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, inhibition of food intake, increase of natriuresis and diuresis, and modulation of rodent β-cell proliferation. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLP-1-based pharmacotherapies are in clinical evaluation for the treatment of obesity. SCOPE OF REVIEW: In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. MAJOR CONCLUSIONS: Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone. The numerous beneficial effects of GLP-1 render this hormone an interesting candidate for the development of pharmacotherapies to treat obesity, diabetes, and neurodegenerative disorders.
The authors' abstract, as published at the source. Molecular Metabolism, 2019 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine